FDA hormone therapy rollback validates Orlando clinic’s early approach

Aspire Rejuvenation Clinic says the FDA’s easing of warnings on hormone therapy and testosterone confirms the hormone-optimization model it has used since 2019. The Orlando-founded practice is now highlighting its growth across multiple states, telemedicine, and future expansion as the regulatory shift broadens patient interest.

Why it matters: - The FDA’s warning changes may make more patients willing to ask about hormone therapy and testosterone treatment. - Aspire Rejuvenation Clinic is using the shift to underscore that its Orlando-born model was built before the stigma started to ease. - The change does not make hormone therapy appropriate for everyone, and some FDA warnings remain in place.

What happened: - The FDA removed boxed warnings tied to cardiovascular disease, breast cancer and dementia from estrogen-containing menopausal hormone therapy in November 2025, with updated labeling taking effect in February 2026. - A warning for endometrial cancer remains on certain estrogen-only products. - The FDA issued class-wide labeling changes for testosterone products in early 2025, removing boxed-warning language about cardiovascular risk after the TRAVERSE clinical trial and adding stronger blood-pressure monitoring language. - Aspire Rejuvenation Clinic, founded in Orlando in 2019, says the federal shift validates a hormone-optimization approach it has used since launch.

The details: - Aspire offers hormone replacement therapy for men and women, testosterone optimization, peptide therapy, medical weight loss and regenerative care. - Licensed medical providers supervise treatments. - The clinic says treatment decisions are based on comprehensive lab work and each patient’s health history, not one-size-fits-all prescriptions. - Tomo Marjanovic, founder and CEO of Aspire Rejuvenation Clinic, said the practice built its model when these therapies still carried heavy warnings and stigma. - Marjanovic said the science has caught up with what the clinic believed about patient care. - Aspire says the Orlando office is its flagship and home base. - The company now includes offices in Pittsburgh and Ebensburg, Pennsylvania, and Plano, Texas. - Aspire plans new clinics in Cleveland and Dubai. - Patients outside the clinic’s physical markets can connect through HIPAA-compliant telemedicine. - The Orlando office is accepting new patients for consultations and does not charge membership fees. - The Orlando clinic is at 8014 Via Dellagio Way, Suite 104, Orlando, FL 32819. - The clinic’s web site is the company’s announcement.

Between the lines: - The FDA label changes may help shift hormone therapy from a fear-driven conversation to a more individualized one. - Aspire is positioning its early adoption as proof that careful hormone optimization can be mainstreamed without abandoning physician oversight. - Marjanovic cautioned that the headline change does not mean every patient should start treatment. - That framing lets Aspire welcome more interest while keeping medical gatekeeping at the center of the message.

What's next: - Aspire says it will keep expanding with planned clinics in Cleveland and Dubai. - The Orlando practice will continue to accept new patients and use telemedicine for broader national access. - Patients considering hormone therapy are likely to see more conversation, but the clinic is signaling that individualized evaluation will remain the standard.

The bottom line: - The FDA’s warning rollback gives Aspire Rejuvenation Clinic a timely tailwind, but the company’s bigger message is that hormone therapy should be guided by labs, history and physician oversight rather than fear or hype.